Boston Scientific completes enrollment in heart failure trial
Boston Scientific has completed the enrollment in its Multicenter Automatic Defibrillator Implantation Trial with Cardiac Resynchronization Therapy (MADIT-CRT).
The company said that the trial will include 1,820 patients and examine the benefits of Boston Scientific’s CRT-defibrillators (CRT-Ds) in a new population of heart failure patients, following in the tradition of MADIT, MADIT II and COMPANION, according to the company.
MADIT-CRT is designed to test whether CRT-Ds can slow the progression of heart failure in heart attack survivors and in those with other forms of impaired heart function, the Natick, Mass.-based company said. Boston Scientific hopes the trial will demonstrate if earlier intervention with CRT-D therapy can slow a patient's progression from early-stage heart failure to late-stage heart failure (Class III and IV).
The company said that the trial will include 1,820 patients and examine the benefits of Boston Scientific’s CRT-defibrillators (CRT-Ds) in a new population of heart failure patients, following in the tradition of MADIT, MADIT II and COMPANION, according to the company.
MADIT-CRT is designed to test whether CRT-Ds can slow the progression of heart failure in heart attack survivors and in those with other forms of impaired heart function, the Natick, Mass.-based company said. Boston Scientific hopes the trial will demonstrate if earlier intervention with CRT-D therapy can slow a patient's progression from early-stage heart failure to late-stage heart failure (Class III and IV).